• Price Momentum

    CNSY is trading near the bottom of its 52-week range and below its 200-day simple moving average.

  • Price change

    The price of CNSY shares has increased $0.14 since the market last closed. This is a 7.82% rise.

  • Closed at $1.93.

    The stock has since risen $0.01 in after-hours trading.

Key terms

About CNSY

Cerenome, Inc. is a clinical-stage pharmaceutical company. The firm focuses on the development of chemotherapeutics and radio therapeutics for rare cancers that address unmet medical and market needs. Its products include Rhenium NanoLiposome and DocePLUS. The company was founded by Ralph E. Holmes and Christopher J. Calhoun in July 1996 and is headquartered in Houston, TX.

Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
     
52-week range
     
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
  • Market cap: $14.65M

    A market capitalization up to $300 million places CNSY in the micro-capitalization category.

Key terms

Smart score

Latest CNSY news

Oct 08, 2026 7:30am ET Cerenome Secures In-Network Agreement with Florida Blue for CNSide® CSF Tumor Cell Enumeration and Molecular Profile Tests Oct 06, 2026 7:30am ET Cerenome Launches CNSide® CSF Molecular Profile Tests Sep 30, 2026 7:30am ET Cerenome Expects $1.55 Million in CNSide® Third Quarter Gross Billings Sep 25, 2026 7:30am ET Cerenome to Hold CNSide® Business Update Call on September 30, 2026 Sep 22, 2026 7:30am ET Cerenome Secures In-Network Agreement with Blue Cross Blue Shield of Michigan, Expanding CNSide® Contracted Coverage to Approximately 158 Million Covered Lives Sep 16, 2026 7:30am ET Cerenome Appoints Samantha Fowlkes as Vice President and Head of Commercial Sales, CNSide Diagnostics Division Sep 10, 2026 7:15am ET Cerenome Announces Up to $20 Million Financing Facility with Royalty-Based Repayment Aug 20, 2026 7:30am ET Cerenome Highlights Presentations at the 2026 SNO/ASCO CNS Metastases Conference Demonstrating Progress in Both Therapeutics and Diagnostics Business Lines Aug 14, 2026 4:15pm ET Cerenome Reports Second Quarter 2026 Financial Results and Business Update Aug 13, 2026 7:30am ET Cerenome Secures In-Network Agreement with Health Care Service Corporation, Expanding CNSide® Contracted Coverage to Over 150 Million Covered Lives Aug 06, 2026 7:30am ET Cerenome Selects XiFin Empower RCM for Revenue Cycle Management and Clearinghouse Services for CNSide Platform

CNSY Financials

1-year income & revenue

  • Total revenue: $5.21M (1Y), $411.00K (Q2)

    Total Revenue decreased 10.49% since last year and decreased 60.02% since last quarter.

  • Net income: -$22.39M (1Y), -$9.01M (Q2)

    Net Income decreased 72.49% since last year and decreased 29.66% since last quarter.

  • Earnings per share: -$7.19 (1Y), -$1.31 (Q2)

    EPS increased 87.71% since last year and decreased 24.89% since last quarter.

Key terms

CNSY Forecasts

analyst rating

  • buy
  • hold
  • sell

We're sorry, but this
information is
temporarily unavailable.

1-year stock price forecast

CNSY Competitors

$ Market cap P/E ratio $ Price 1d change 52-week range
  • How competitors are chosen

    CNSY's competitors are included in the Health Technology sector and Pharmaceuticals: Major group

  • Market cap: $14.65M

    A market capitalization up to $300 million places CNSY in the micro-capitalization category.

Key terms